TRANSPLANT BIOMEDICALS received last June 20 in Madrid at the gala organized by the European Institute of Design (IED) in the gardens of the Embassy of Italy, the award for the Best Proposal for Entrepreneurship in the Management category. The IED Design Awards annually reward creative teams, products or services that provide a new vision, as well as an improvement in the quality of life of citizens and a value that takes into account market demands.
TRANSPLANT BIOMEDICALS is a company specialized in research and development of medical devices for transport and preservation of organs, tissues and cells. With this award, the company ends a first semester of 2019 with the recent announcement of positive results in interim analysis in the EMERGE study, its first clinical study in kidney transplant, with VIVIAN® KIDNEY, a medical device used for transport and preservation of kidneys in patients undergoing transplantation.
At the IED Design Awards gala, Katharine Hamnett was also awarded as an honorary prize, one of the most prominent activists in the world of fashion, fighting for the sustainability of the sector for more than 30 years and known throughout the world for be one of the names of contemporary British fashion. They also received awards in the different Visual, Design, Fashion and Management categories, companies such as Coca-Cola, Toyota, Inditex, Editorial Santillana, Unicoos, Room Mate Hotels and institutions such as the Reina Sofía Museum. TRANSPLANT BIOMEDICALS was the only company awarded in the field of health.
"At TRANSPLANT BIOMEDICALS we feel doubly rewarded, on the one hand by the award given by IED Madrid for our contribution to the improvement of people's health, and also for the fortune of devoting ourselves to a health sector with great emotional return, since organ transplantation is characterized by the altruism of society in the donation of organs and by having the ability to participate in a gift of life that means for us to transport an organ that saves a life. That is why this award is dedicated to the entire TRANSPLANT BIOMEDICALS team that has conceived and developed VIVIAN®, "said Dr. Joan Salgado, CEO of TRANSPLANT BIOMEDICALS, at the award ceremony.
About VIVIAN®
VIVIAN® is a medical device for organ ex-vivo treatment with Hypothermic Ultrasound Preservation Technology (HUPT), a unique patented technology combining controlled hypothermia and low frequency/energy ultrasound. Previous functional preclinical trials have shown a significant improvement in graft function in liver and kidney models and a relevant increase in recipient survival. VIVIAN® is able to activate new intrinsic protective signalling pathways in the preservation of organs, tissue and cells of great scientific and clinical relevance.
About TRANSPLANT BIOMEDICALS
TRANSPLANT BIOMEDICALS operates in the medical device sector, we aim to develop and commercialize a new generation of medical technologies that advance organ, tissue and cellular preservation with the purpose of improving patient outcomes and the care provided by their caregivers.
TRANSPLANT BIOMEDICALS has the opportunity to become a game changer in organ transplantation by offering a new generation of medical technologies aimed to improve organ preservation. VIVIAN® is expected to address current unmet medical needs and the shortcomings of the standard-of-care in organ preservation by offering a new generation, disposable and costeffective organ preservation device able to increase preservation efficacy, improve early graft dysfunction, enhance the poor post-operative outcomes after organ transplantation from standard and extended criteria donors, and maximize the usage of the available organ pool reducing thus the waiting list for transplant
TRANSPLANT BIOMEDICALS pursues a total target market of €1.1 billion and now is seeking €13.6M in order to complete the clinical development, final product and market launch of VIVIAN® in kidney transplantation and further pursue early pipeline development activities.
The research team observed changes in head circumf...
AtCDF3 gene induced greater production of sugars a...
Un estudio con datos de los últimos 35 años, ind...
En nuestro post hablamos sobre este interesante tipo de célula del...
Research led by IIBB-CSIC and CIBEREHD scientists identifies S-adenosy...
